tiprankstipranks
Advertisement
Advertisement
Apellis price target raised to $41 from $20 at Mizuho
PremiumThe FlyApellis price target raised to $41 from $20 at Mizuho
22d ago
Apellis downgraded to Neutral from Buy at Roth Capital
Premium
The Fly
Apellis downgraded to Neutral from Buy at Roth Capital
22d ago
Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
Premium
The Fly
Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
23d ago
Apellis downgraded to Market Perform from Outperform at Raymond James
PremiumThe FlyApellis downgraded to Market Perform from Outperform at Raymond James
23d ago
Hold Rating on Apellis Reflects Biogen Takeover Cap on Upside and Limited Near-Term Catalysts
Premium
Ratings
Hold Rating on Apellis Reflects Biogen Takeover Cap on Upside and Limited Near-Term Catalysts
23d ago
Apellis Pharmaceuticals to be Acquired by Biogen in Merger
Premium
Company Announcements
Apellis Pharmaceuticals to be Acquired by Biogen in Merger
23d ago
Apellis downgraded to Hold from Buy at Jefferies
PremiumThe FlyApellis downgraded to Hold from Buy at Jefferies
24d ago
Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
Premium
The Fly
Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
24d ago
Apellis price target raised to $41 from $25 at Morgan Stanley
Premium
The Fly
Apellis price target raised to $41 from $25 at Morgan Stanley
24d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100